Surrozen, Inc. (SRZN)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Surrozen, Inc. (SRZN) trades at $28.00 with AI Score 70/100 (Buy). Surrozen, Inc. is a biotechnology company focused on discovering and developing drug candidates that modulate the Wnt pathway for tissue repair and regeneration. Market cap: 240M, Sector: Healthcare.
Last analyzed: Feb 4, 2026Surrozen, Inc. (SRZN) Healthcare & Pipeline Overview
Surrozen, Inc. pioneers tissue regeneration through Wnt pathway modulation, offering a unique approach to treating severe diseases with its innovative antibody pipeline, targeting a multi-billion dollar market and positioning the company for significant growth in the regenerative medicine space.
Investment Thesis
Surrozen presents a notable research candidate due to its innovative approach to tissue regeneration through Wnt pathway modulation. The company's lead candidates, SZN-043 and SZN-1326, target significant unmet needs in severe liver disease and intestinal crypt diseases, respectively. With a market capitalization of $0.20 billion and a gross margin of 100.0%, Surrozen has the potential for substantial growth as its pipeline advances through clinical trials. Key value drivers include successful clinical trial outcomes, strategic partnerships, and potential FDA approvals. The company's focus on tissue-specific antibodies offers a differentiated approach compared to traditional therapies, positioning Surrozen as a leader in the regenerative medicine space. Upcoming clinical trial data releases for SZN-043 and SZN-1326 will serve as major catalysts for the stock.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.20B reflects the company's current valuation and growth potential in the biotechnology sector.
- Gross Margin of 100.0% indicates efficient operations and high potential profitability upon commercialization of drug candidates.
- Beta of 0.58 suggests lower volatility compared to the overall market, potentially appealing to risk-averse investors.
- Focus on Wnt pathway modulation provides a targeted approach to tissue regeneration, differentiating Surrozen from competitors.
- Pipeline includes SZN-043 for severe liver disease and SZN-1326 for intestinal crypt diseases, addressing significant unmet medical needs.
Competitors & Peers
Strengths
- Innovative Wnt pathway modulation technology.
- Targeted tissue-specific antibody approach.
- Strong intellectual property portfolio.
- Experienced management team.
Weaknesses
- Limited number of drug candidates in pipeline.
- High R&D costs and long development timelines.
- Reliance on successful clinical trial outcomes.
- Negative profit margin.
Catalysts
- Upcoming: Clinical trial data release for SZN-043 in severe liver disease.
- Upcoming: Clinical trial data release for SZN-1326 in intestinal crypt diseases.
- Ongoing: Potential strategic partnerships with pharmaceutical companies.
- Ongoing: Advancement of pipeline candidates through preclinical and clinical development.
Risks
- Potential: Failure of clinical trials for SZN-043 and SZN-1326.
- Potential: Regulatory delays or rejection of drug candidates.
- Ongoing: Competition from other biotechnology companies.
- Ongoing: High R&D costs and long development timelines.
- Potential: Patent challenges and intellectual property disputes.
Growth Opportunities
- Expansion of Pipeline: Surrozen has the opportunity to expand its pipeline beyond SZN-043 and SZN-1326 by developing additional tissue-specific antibodies targeting other diseases. The market for regenerative medicine is vast, encompassing a wide range of indications such as retinal, corneal, lung, kidney, cochlea, skin, pancreas, and central nervous system diseases. Successful development and commercialization of new drug candidates could significantly increase Surrozen's revenue and market share. Timeline: Ongoing.
- Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies could provide Surrozen with access to additional funding, expertise, and resources. These partnerships could accelerate the development and commercialization of Surrozen's drug candidates, increasing their chances of success. The market for pharmaceutical collaborations is highly competitive, but Surrozen's innovative technology and promising pipeline make it an attractive partner. Timeline: Ongoing.
- Successful Clinical Trials: Positive results from clinical trials of SZN-043 and SZN-1326 would be a major catalyst for Surrozen's growth. Successful trials would validate the company's technology and increase the likelihood of regulatory approval, paving the way for commercialization. The market for liver disease and intestinal crypt disease therapies is substantial, and Surrozen could capture a significant share with effective treatments. Timeline: Upcoming.
- Regulatory Approvals: Obtaining regulatory approvals from the FDA and other regulatory agencies is crucial for Surrozen's success. Approval of SZN-043 and SZN-1326 would allow the company to commercialize these drugs and generate revenue. The regulatory approval process is lengthy and complex, but Surrozen's experienced management team and strong scientific data increase its chances of success. Timeline: Ongoing.
- Geographic Expansion: Expanding into new geographic markets could provide Surrozen with access to a larger patient population and increased revenue opportunities. The global market for regenerative medicine is growing rapidly, and Surrozen could benefit from establishing a presence in key regions such as Europe and Asia. This expansion would require significant investment, but the potential returns are substantial. Timeline: Ongoing.
Opportunities
- Expansion of pipeline into new disease areas.
- Strategic partnerships with larger pharmaceutical companies.
- Positive clinical trial results for SZN-043 and SZN-1326.
- Regulatory approvals and commercialization of drug candidates.
Threats
- Competition from other biotechnology companies.
- Failure of clinical trials.
- Regulatory hurdles and delays.
- Patent challenges and intellectual property disputes.
Competitive Advantages
- Proprietary Wnt pathway modulation technology.
- Tissue-specific antibody development platform.
- Strong intellectual property portfolio.
- Experienced management team with expertise in regenerative medicine.
About SRZN
Founded in 2015 and headquartered in South San Francisco, California, Surrozen, Inc. is a biotechnology company dedicated to discovering and developing innovative drug candidates that selectively modulate the Wnt pathway. This pathway is crucial for tissue repair and regeneration, and Surrozen is harnessing its potential to address a wide range of diseases. The company's approach involves developing tissue-specific antibodies designed to stimulate regeneration in specific areas of the body. Surrozen's pipeline includes SZN-043, a tissue-specific R-spondin mimetic developed for the treatment of severe liver disease. Additionally, SZN-1326, a bi-specific full-length human antibody, directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors expressed in intestinal crypts. Surrozen's technology has potential applications across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. By focusing on tissue-specific regeneration, Surrozen aims to provide targeted therapies with improved efficacy and reduced side effects, addressing unmet medical needs in multiple therapeutic areas.
What They Do
- Discovers drug candidates to modulate the Wnt pathway.
- Develops tissue-specific antibodies for targeted therapies.
- Focuses on tissue repair and regeneration.
- Targets diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
- Develops SZN-043 for severe liver disease.
- Develops SZN-1326 for intestinal crypt diseases.
- Utilizes bi-specific full-length human antibodies.
Business Model
- Develops and patents novel drug candidates.
- Conducts preclinical and clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approvals from agencies like the FDA.
- Commercializes approved drugs directly or through partnerships.
Industry Context
Surrozen operates within the rapidly evolving biotechnology industry, specifically targeting the regenerative medicine market. The industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements. Surrozen's focus on Wnt pathway modulation positions it within a niche segment of tissue regeneration, offering a differentiated approach compared to traditional therapies. The regenerative medicine market is projected to experience substantial growth, driven by an aging population and increasing prevalence of chronic diseases. Surrozen competes with companies developing therapies for similar indications, including AGEN, ATOS, CGTX, GLSI, and IMMX, but its tissue-specific antibody approach provides a potential competitive advantage.
Key Customers
- Patients suffering from severe liver diseases.
- Patients with intestinal crypt diseases.
- Healthcare providers prescribing regenerative therapies.
- Pharmaceutical companies seeking partnerships for novel drug candidates.
Financials
Chart & Info
Surrozen, Inc. (SRZN) stock price: $28.00 (+1.86, +7.12%)
Latest News
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SRZN.
Price Targets
Consensus target: $40.00
MoonshotScore
What does this score mean?
The MoonshotScore rates SRZN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Surrozen, Inc. Stock: Key Questions Answered
What does Surrozen, Inc. do?
Surrozen, Inc. is a biotechnology company focused on discovering and developing drug candidates that selectively modulate the Wnt pathway for tissue repair and regeneration. Their innovative approach involves creating tissue-specific antibodies designed to stimulate regeneration in specific areas of the body. The company's pipeline includes SZN-043 for severe liver disease and SZN-1326 for intestinal crypt diseases. Surrozen aims to provide targeted therapies with improved efficacy and reduced side effects, addressing unmet medical needs in multiple therapeutic areas, positioning themselves as a key player in regenerative medicine.
Is SRZN stock worth researching?
SRZN stock presents a speculative investment opportunity with high potential reward and significant risk. The company's innovative Wnt pathway modulation technology and targeted tissue-specific antibody approach offer a differentiated approach to regenerative medicine. However, the company's negative profit margin of -2411.4% and reliance on successful clinical trial outcomes pose significant risks. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in SRZN. Positive clinical trial data could drive significant upside, while negative results could lead to substantial losses.
What are the main risks for SRZN?
The main risks for Surrozen include the potential failure of clinical trials for its lead drug candidates, SZN-043 and SZN-1326. Clinical trials are inherently risky, and negative results could significantly impact the company's valuation and future prospects. Regulatory delays or rejection of drug candidates also pose a significant risk. Surrozen also faces competition from other biotechnology companies developing therapies for similar indications. High R&D costs and long development timelines are also ongoing risks that could strain the company's financial resources. Patent challenges and intellectual property disputes could also negatively impact Surrozen's competitive position.
What are the key factors to evaluate for SRZN?
Surrozen, Inc. (SRZN) currently holds an AI score of 70/100, indicating high score. Analysts target $40.00 (+43% from $28.00). Key strength: Innovative Wnt pathway modulation technology.. Primary risk to monitor: Potential: Failure of clinical trials for SZN-043 and SZN-1326.. This is not financial advice.
How frequently does SRZN data refresh on this page?
SRZN prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven SRZN's recent stock price performance?
Recent price movement in Surrozen, Inc. (SRZN) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $40.00 implies 43% upside from here. Notable catalyst: Innovative Wnt pathway modulation technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider SRZN overvalued or undervalued right now?
Determining whether Surrozen, Inc. (SRZN) is overvalued or undervalued requires examining multiple metrics. Analysts target $40.00 (+43% from current price), suggesting analysts see upside potential. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying SRZN?
Before investing in Surrozen, Inc. (SRZN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Investment in biotechnology companies is inherently risky.